Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
49 hedge funds and large institutions have $166M invested in Intra-Cellular Therapies Inc. in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 11 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
11% less funds holding
Funds holding: 55 → 49 (-6)
19% less capital invested
Capital invested by funds: $204M → $166M (-$38M)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.51M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$2.17M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$2.12M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$762K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$534K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$4.03M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.59M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$1.37M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$984K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$344K |
ITCI Hedge Fund Activity: Q3 2014 in Review
49 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2014, worth a combined $166M — down 19% from $204M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ITCI and 5 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 21 added.
The largest buyer was Adage Capital Partners, adding an estimated $4.51M. The largest seller was Franklin Resources, cutting an estimated $4.03M.
- 49 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2014, down from 55 in Q2 2014.
- Funds reported $166M of Intra-Cellular Therapies Inc. stock for Q3 2014, down 19% quarter-over-quarter.
- 5 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2014 and 11 closed out, a net change of -6 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q3 2014 was Adage Capital Partners, an estimated $4.51M added.
- The largest Intra-Cellular Therapies Inc. seller in Q3 2014 was Franklin Resources, an estimated $4.03M sold.
Based on aggregated 13F filings for Q3 2014.